Bayer Pharma has licensed exclusive rights to develop and commercialise Trius Therapeutics’ torezolid phosphate (TR-701) for acute bacterial skin and skin structure infections (aBSSSI) and pneumonia in China, Japan and all other countries in Asia, Africa, Latin America and the Middle East, excluding North and South Korea. Trius retains full rights to the drug in the US, Canada and the EU.